Tag: Dr Kiran Mazumdar Shaw
Biocon & Mylan’s biosimilar ‘Trastuzumab’ gets approval from Brazilian regulator
Co-developed by Biocon and Mylan, this is the first biosimilar Trastuzumab to be approved in Brazil and is indicated for the treatment of overexpressing HER2positive metastatic breast cancer. The product will be marketed by the Libbs Farmaceutica........
BIRAC celebrates its 5th birthday amid resolve to make India a...
The intense discussions at the 2-day event to celebrate the 5th foundation day of the Biotechnology Research Assistance Council, were focused around the theme “BIRAC@5: Impacting the Biotech Ecosystem”........
ABLE selects BEST student entrepreneurial teams for 2016
ABLE announces BEST 2016 winners, the annual list of five teams comprising of young post graduate teams who wish to pursue the spirit of biotech innovation and business......
US-FDA accepts Mylan & Biocon’s joint application on biosimilar Trastuzumab
While the Biologics License Application (BLA) for MYL-1401O has been accepted by the United States FDA, if approved, it has the potential to be the first biosimilar Trastuzumab in the US....
BioVoice eMag December 2016 – January 2017 Issue-8 Volume-1
BioVoice eMag December 2016 - January 2017 Issue-8 Volume-1:
This edition of BioVoice features detailed cover story on demonetization move and the immediate steps taken...
Dr Kas Subramanian joins Syngene International
Having headed the R&D division at the Strand Life Sciences, Dr Kalyanasundaram Subramanian will now spearhead the bioinformatics initiative....
Biocon registers strong performance, profits up by 17%
Biocon in the first quarter of the financial year 2016-17, has reported the revenues of Rs 952 crore; net profit up by 17 percent at Rs 147 crore ....
India’s first siRNA drug to treat rare eye disease soon
The elderly patients afflicted by a rare eye disease, NAION (non-arteritic ischemic optic neuropathy) that leads...
Indian bio-economy bigger than $35 billion, reveals ABLE report
While the report released by Association of Biotechnology Led Enterprises (ABLE) at the ongoing BIO..